IL2 and neoplasm: For instance, by combining high-affinity CD16 V158 FcγRIIIa receptor and IL-2 expression in engineered NK92 cells, enhanced lysis of tumor cells was observed with diverse combinations of monoclonal antibodies and target cells [7].